Evinacumab (Evkeeza)
- Status:
- Do Not Prescribe (DNP)
- Decision Date:
- November 2022
Comments
Use as an adjunct to diet and other low-density lipoprotein cholesterol
lowering therapies for the treatment of adult and adolescent patients aged ≥12
years with homozygous familial hypercholesterolaemia. Await clinician requestBlack Drug Classifications
- 2: Have a lack of data on safety compared with standard therapy
- 4: Have a lack of data on cost-effectiveness compared with standard therapy
- 5: Less cost-effective than current standard therapy
search again